OverviewSuggest Edit

Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
TypePublic
Founded2006
HQSan Diego, US
Websitesorrentotherapeutics.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)310(-18%)
Job Openings52
Revenue (FY, 2019)$31.4 M(+49%)
Share Price (Sept 2020)$9.6 (-10%)
Cybersecurity ratingAMore

Key People/Management at Sorrento Therapeutics

Hui Li

Hui Li

Vice President of Business Development and General Manager of China Operations
Henry Ji

Henry Ji

Chairman, President and CEO
Jerome Zeldis

Jerome Zeldis

Chief Medical Officer
Mike Royal

Mike Royal

Chief Medical Officer
Edgar Lee

Edgar Lee

Director
David Lemus

David Lemus

Director
Show more

Sorrento Therapeutics Office Locations

Sorrento Therapeutics has an office in San Diego
San Diego, US (HQ)
4955 Directors Pl
San Diego, US
9380 Judicial Dr
Show all (2)

Sorrento Therapeutics Financials and Metrics

Sorrento Therapeutics Revenue

Sorrento Therapeutics's revenue was reported to be $31.43 m in FY, 2019
USD

Revenue (Q2, 2020)

9.0m

Net income (Q2, 2020)

(85.0m)

EBIT (Q2, 2020)

(47.7m)

Market capitalization (23-Sept-2020)

2.4b

Closing stock price (23-Sept-2020)

9.6

Cash (30-Jun-2020)

24.4m

EV

2.6b
Sorrento Therapeutics's current market capitalization is $2.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

529.2k583.8k460.1k3.8m4.6m8.2m151.9m21.2m31.4m

Revenue growth, %

731%20%78%

Cost of goods sold

4.4k2.0m2.0m811.0k3.9m7.1m

Gross profit

455.7k1.8m2.6m7.3m147.9m14.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Revenue

74.2k91.8k110.1k217.1k134.5k134.1k83.8k976.0k775.0k1.3m977.0k1.2m1.1m988.0k902.0k2.2m4.9m4.7m121.9m6.2m3.9m4.1m6.1m7.7m9.0m

Cost of goods sold

563.0k510.0k527.0k509.0k314.0k604.0k359.0k295.0k418.0k1.1m816.0k1.1m1.3m1.2m2.2m2.3m

Gross profit

413.0k265.0k749.0k468.0k859.0k499.0k629.0k607.0k1.8m3.8m3.8m120.8m4.9m2.7m1.9m3.8m

Gross profit Margin, %

42%34%59%48%73%45%64%67%81%78%83%99%79%69%47%62%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.5m5.1m31.7m71.9m39.0m82.4m20.4m158.7m

Accounts Receivable

2.2m3.8m

Prepaid Expenses

29.9k80.9k4.9m6.6m

Current Assets

3.6m5.3m32.6m73.9m141.0m89.7m29.7m179.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Cash

2.9m2.3m2.4m7.6m6.4m9.6m5.8m6.4m29.9m50.2m44.3m60.5m51.7m59.1m20.8m98.2m66.5m33.9m53.7m38.3m24.3m46.8m135.4m91.0m21.9m24.4m

Accounts Receivable

657.0k576.0k986.0k784.0k898.0k622.0k1.1m867.0k526.0k2.3m2.4m1.7m3.9m7.4m10.0m13.8m

Prepaid Expenses

4.8k41.3k22.6k13.6k66.8k688.7k75.0k407.6k626.0k705.0k586.0k879.0k1.2m731.0k1.9m556.0k1.1m3.3m2.4m2.3m6.2m5.5m14.7m14.4m

Inventories

4.6m3.0m2.4m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.2m)(4.8m)(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)(363.0m)

Depreciation and Amortization

159.2k293.3k1.3m3.2m2.4m2.9m7.1m9.1m11.0m

Inventories

(3.2m)

Accounts Payable

42.9k(23.2k)878.6k(497.0k)(2.7m)3.7m1.6m3.6m10.2m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Sorrento Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Sorrento Therapeutics Online and Social Media Presence

Embed Graph

Sorrento Therapeutics News and Updates

Sorrento Therapeutics Stock Is An Interesting Pick At $9

Despite a massive 5x rise since the March 23 lows of this year, at the current price of around $9 per share we believe Sorrento Therapeutics stock has more room for growth. SRNE stock shot up 13% in Thursday’s trade owing to the U.S. FDA clearing its Covid-19 antibody - COVI-Guard (STI-1499)...

Thinking about buying stock in Sorrento Therapeutics, Herman Miller, iBio Inc, TOP Ships, or Aurora Cannabis?

NEW YORK, Sept. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, MLHR, IBIO, TOPS, and ACB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Sorrento Therapeutics soars 44% after FDA green-lights COVID-19 antibody trial (SRNE)

Summary List Placement Sorrento Therapeutics soared on Thursday after the biotechnology firm received clearance from the FDA to proceed with a phase I clinical trial evaluating COVI-GUARD, a COVID-19 antibody test. Sorrento is targeting a potential emergency use authorization submission to the FDA…

Thinking about buying stock in Cassava Sciences, Mersana Therapeutics, Sorrento Therapeutics, Dynavax Technologies, or Co-Diagnostics?

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, MRSN, SRNE, DVAX, and CODX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSK, ATRA, FCEL, SRNE, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in iBio Inc, Virgin Galactic, Sorrento Therapeutics, Adamis Pharmaceuticals, or Plug Power?

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, SPCE, SRNE, ADMP, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Sorrento Therapeutics Frequently Asked Questions

  • When was Sorrento Therapeutics founded?

    Sorrento Therapeutics was founded in 2006.

  • Who are Sorrento Therapeutics key executives?

    Sorrento Therapeutics's key executives are Hui Li, Henry Ji and Jerome Zeldis.

  • How many employees does Sorrento Therapeutics have?

    Sorrento Therapeutics has 310 employees.

  • What is Sorrento Therapeutics revenue?

    Latest Sorrento Therapeutics annual revenue is $31.4 m.

  • What is Sorrento Therapeutics revenue per employee?

    Latest Sorrento Therapeutics revenue per employee is $101.4 k.

  • Who are Sorrento Therapeutics competitors?

    Competitors of Sorrento Therapeutics include Celyad, Alnylam Pharmaceuticals and Luna Innovations.

  • Where is Sorrento Therapeutics headquarters?

    Sorrento Therapeutics headquarters is located at 4955 Directors Pl, San Diego.

  • Where are Sorrento Therapeutics offices?

    Sorrento Therapeutics has an office in San Diego.

  • How many offices does Sorrento Therapeutics have?

    Sorrento Therapeutics has 2 offices.